MATERIAL SAFETY DATA SHEET

Product Name: Diphenhydramine Hydrochloride Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name: Hospira, Inc.
And Address: 275 North Field Drive
            Lake Forest, Illinois 60045
            USA

Note: Hospira, formerly the Hospital Products Division of Abbott Laboratories, was created as an independent company in May 2004.

Emergency Telephone: CHEMTREC: 800 424-9300
                      Hospira, Inc.: 224 212-2055

Product Name: Diphenhydramine Hydrochloride Injection, USP
Synonyms: Benadryl

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Chemical Formula</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine Hydrochloride</td>
<td>C_{17}H_{22}ClNO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component</th>
<th>Approximate Percent by Weight</th>
<th>CAS Number</th>
<th>RTECS Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine Hydrochloride</td>
<td>5</td>
<td>147-24-0</td>
<td>KR7000000</td>
</tr>
<tr>
<td>Water</td>
<td>95</td>
<td>7732-18-5</td>
<td>ZC0110000</td>
</tr>
</tbody>
</table>

3. HAZARD INFORMATION

Emergency Overview: Diphenhydramine hydrochloride is an antihistamine used for relief of symptoms associated with allergies or colds, and for the treatment of symptoms associated with motion sickness. Toxic by ingestion. May cause nervous system effects.

Occupational Exposure: Information from occupational exposure is not available.

Signs and Symptoms: The most frequently observed side effects include sedation, sleepiness, breathing difficulty, disturbed coordination, hypotension, gastrointestinal upset and thickened bronchial secretions.

Medical Conditions: Clinical experience suggests narrow-angle glaucoma, peptic ulcers and other gastrointestinal disorders, bladder obstruction, prostatic hypertrophy, asthma, hyperthyroid, cardiovascular disease, hypertension and concurrent use of central nervous system depressants or monoamine oxidase inhibitor therapy.

4. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Product Name: Diphenhydramine Hydrochloride Injection, USP

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable

Fire & Explosion Hazard: None

Extinguishing Media: Use extinguishing media appropriate for primary cause of fire.

Special Fire Fighting Procedures: No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal: Absorb with suitable material and dispose of materials according to applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

Handling: No special handling required.

Storage: No special storage required for hazard control. For product protection store at 20 - 25°C (68 - 77°F).

Special Precautions: No special precautions.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Exposure Guideline</th>
<th>Exposure Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Component</td>
<td>OSHA-PEL</td>
</tr>
<tr>
<td>Diphenhydramine Hydrochloride</td>
<td>8 hr TWA: Not Established</td>
</tr>
</tbody>
</table>

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit
ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.
EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Respiratory Protection: Respiratory protection is not needed during normal product use.

Skin Protection: If contact with unprotected skin is likely, glove use is prudent practice.
Product Name: Diphenhydramine Hydrochloride Injection, USP

Eye Protection
Eye protection is not required during expected product use conditions but may be warranted if eye contact is likely.

Engineering Controls
Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance/Physical</td>
<td>Clear liquid</td>
</tr>
<tr>
<td>State</td>
<td></td>
</tr>
<tr>
<td>Odor</td>
<td>Not Determined</td>
</tr>
<tr>
<td>Boiling Point</td>
<td>Approximately that of water (100°C, 212°F)</td>
</tr>
<tr>
<td>Freezing Point</td>
<td>Approximately that of water (0°C, 32°F)</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>Approximately that of water (17.5 mm Hg at 20°C)</td>
</tr>
<tr>
<td>Vapor Density (Air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Bulk Density</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Density</td>
<td>1.005 g/ml</td>
</tr>
<tr>
<td>Solubility</td>
<td>Not Determined</td>
</tr>
<tr>
<td>pH</td>
<td>5.7 – 6.5</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Chemical Stability
Stable under standard use and storage conditions.

Incompatibilities
May react with strong oxidizing agents.

Hazardous Decomposition Products
May emit toxic smoke.

Hazardous Polymerization
Will not occur.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:

<table>
<thead>
<tr>
<th>Ingredient(s)</th>
<th>Percent</th>
<th>Test Type</th>
<th>Value</th>
<th>Units</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphenhydramine HCL</td>
<td>100</td>
<td>LD50</td>
<td>114-500</td>
<td>mg/kg</td>
<td>Rats, mice, and guinea pigs</td>
</tr>
</tbody>
</table>

LD50 is the dosage producing 50% mortality.
Product contains approximately 5% Diphenhydramine.

Mutagenicity
Not Determined

Reproductive Effects
No effects identified.

Target Organ Effects
Possible target organs include skin, eyes, and the central nervous, gastrointestinal, and cardiovascular systems. In animal studies, there is limited evidence of fetotoxicity and possible cleft palate formation.

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity
Not Available

3
Product Name: Diphenhydramine Hydrochloride Injection, USP

13. DISPOSAL CONSIDERATIONS:
Waste Disposal
Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal
Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION
DOT
Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION
TSCA Status
Not Regulated
CERCLA Status
Not Regulated
SARA Status
Not Regulated
RCRA Status
Not Regulated
PROP 65 (Calif.)
Not Regulated

Notes: TSCA Toxic Substance Control Act
CERCLA US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
SARA Superfund Amendments and Reauthorization Act
RCRA US EPA, Resource Conservation and Recovery Act
Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator T. Straits MPH, CIH
Date Prepared September 15, 2005

Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.